ReviewExpert review of gastroenterology & hepatology2011
The role of experimental models in developing new treatments for irritable bowel syndrome.
Review in Expert review of gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- What Has Longitudinal 'Omics' Studies Taught Us about Irritable Bowel Syndrome? A Systematic Review.Metabolites · 2023Review
- Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.FASEB bioAdvances · 2022Article
- Enteric pathogens induce tissue tolerance and prevent neuronal loss from subsequent infections.Cell · 2021Article
- Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male mice.Scientific reports · 2021Article
- Beyond Immunity: Underappreciated Functions of Intestinal Macrophages.Frontiers in immunology · 2021Review
- Oral Phyto-thymol ameliorates the stress induced IBS symptoms.Scientific reports · 2020Article
- Article
- Review
- Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity.The Journal of pharmacology and experimental therapeutics · 2019Article
- Early weaning stress induces chronic functional diarrhea, intestinal barrier defects, and increased mast cell activity in a porcine model of early life adversity.Neurogastroenterology and motility · 2017Article
- Impaired intestinal barrier function and relapsing digestive disease: Lessons from a porcine model of early life stress.Neurogastroenterology and motility · 2017Review
- Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.Journal of cellular and molecular medicine · 2017Article
- Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis.Current neuropharmacology · 2016Review
- Towards a systems view of IBS.Nature reviews. Gastroenterology & hepatology · 2015Review
- Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Frontiers in psychiatry · 2015Review
- Behavioral and molecular processing of visceral pain in the brain of mice: impact of colitis and psychological stress.Frontiers in behavioral neuroscience · 2015Article
- Gut pain & visceral hypersensitivity.British journal of pain · 2013Article
- Drug development for the irritable bowel syndrome: current challenges and future perspectives.Frontiers in pharmacology · 2013Article
- Characterization of the Visceral Antinociceptive Effect of Glial Glutamate Transporter GLT-1 Upregulation by Ceftriaxone.ISRN Pain · 2013Article
- Stress and visceral pain: from animal models to clinical therapies.Experimental neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Irritable bowel syndrome (IBS) is characterized by chronic, recurrent abdominal pain and altered bowel habits and is currently defined by symptom criteria and the absence of detectable organic disease. The underlying pathophysiology remains incompletely understood. Despite considerable efforts by the scientific community and the pharmaceutical industry to develop novel pharmacological treatments aimed at chronic visceral pain, the traditional approach to identifying and evaluating novel drugs for this target have largely failed to translate into effective IBS treatments. However, several novel drugs aimed at normalizing bowel movements have produced clinical effects, not only on the primary target, but also on pain and discomfort. While some of the commonly used experimental animal models for the pain dimension of IBS have some face and construct validity, the predictive validity of most of the models is either unknown, or has been disappointing. A reverse translational approach is proposed, which is based on identification and characterization of brain endophenotypes in patients, followed by translation of these endophenotypes for pharmacological studies in rodent models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.